Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 89 publications
124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.
Journal: JAMA
Published: August 30, 2026
Plain language summary of how acoramidis affects the total number of heart problems over time in people with ATTR-CM: findings from the ATTRibute-CM study.
Journal: Future cardiology
Published: August 03, 2026
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis With Cardiomyopathy: Insights From HELIOS-B.
Journal: Journal of the American College of Cardiology
Published: June 22, 2026
Long-term effects of acoramidis on mortality in variant transthyretin amyloid cardiomyopathy, including p.Val142Ile: findings from the open-label extension of ATTRibute-CM.
Journal: European journal of heart failure
Published: June 15, 2026
Promise and Practical Limits of Multimodal AI for Cardiac Amyloidosis Detection.
Journal: Circulation. Cardiovascular imaging
Published: May 29, 2026
Design and rationale of the Research with EVuzamitide to Evaluate for cardiac AmyLoidosis (REVEAL) positron emission tomography study: A study of 124I-evuzamitide to diagnose cardiac amyloidosis.
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: May 21, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial.
Journal: JAMA cardiology
Published: March 30, 2026
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.
Journal: European journal of heart failure
Published: March 09, 2026
Multimodality imaging in cardiac amyloidosis: When and how to combine nuclear techniques with echocardiography and cardiac magnetic resonance imaging.
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: March 02, 2026
Assessment of cardiac involvement in rare forms of amyloidosis using positron emission tomography/computed tomography with 124I-evuzamitide (124I-p5+14, AT-01).
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: February 05, 2026
Assessment of Cardiac Involvement in Rare Forms of Amyloidosis Using PET/CT with 124I-Evuzamitide (124I-p5+14, AT-01).
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: February 05, 2026
Last Updated: 09/26/2026